Article
Biochemistry & Molecular Biology
Chaima Cherif, Dang Tan Nguyen, Clement Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El Kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthelemy, Daniel Birnbaum, Francois Bertucci, David Taieb, Palma Rocchi
Summary: Menin (MEN1) protein is highly regulated by HSP27, overexpressed in high-grade PC and CRPC, and high MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin helps inhibit CRPC cell proliferation, tumor growth, and restore chemotherapeutic sensitivity.
Article
Cell Biology
Sadia Sarwar, Viacheslav M. Morozov, Hamsa Purayil, Yehia Daaka, Alexander M. Ishov
Summary: Androgen ablation therapy is the standard treatment for newly diagnosed prostate cancer patients. However, the relapse of castration-resistant prostate cancer (CRPC) often leads to metastasis and disease lethality. Current therapies for metastatic CRPC are limited due to resistance to Taxanes. In this study, we found that inhibition of the mitotic checkpoint kinase Mps1 enhances the efficacy of Taxanes treatment, providing a potential new therapeutic target for managing therapy-resistant metastatic CRPC.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Tianyan Wang, Martuza Sarwar, Jonathan B. Whitchurch, Hilary M. Collins, Tami Green, Julius Semenas, Amjad Ali, Christopher J. Roberts, Ryan D. Morris, Madlen Hubert, Sa Chen, Zahra El-Schich, Anette G. Wingren, Thomas Grundstroem, Richard Lundmark, Nigel P. Mongan, Lena Gunhaga, David M. Heery, Jenny L. Persson
Summary: This study identifies the role of PIP5K1α in promoting the growth and invasion of castration-resistant prostate cancer. The study also reveals the importance of the N-terminal domain of PIP5K1α and its function as an upstream regulator of androgen receptor and its target genes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Cell Biology
Shimiao Zhu, Zhao Yang, Zheng Zhang, Hongli Zhang, Songyang Li, Tao Wu, Xuanrong Chen, Jianing Guo, Aixiang Wang, Hao Tian, Jianpeng Yu, Changwen Zhang, Lei Su, Zhiqun Shang, Changyi Quan, Yuanjie Niu
Summary: Resistance to antiandrogen is lethal for castration-resistant prostate cancer (CRPC). In this study, we identified HOXB3 as an independent risk factor for progression and death in metastatic CRPC. We demonstrated that HOXB3 activation was associated with WNT pathway genes expression, and suppression of HOXB3 sensitized CRPC to abiraterone treatment. Our findings suggest that targeting HOXB3 may benefit a subgroup of CRPC resistant to antiandrogen therapy.
CELL DEATH & DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Stephen Y. C. Choi, Caroline Fidalgo Ribeiro, Yuzhuo Wang, Massimo Loda, Stephen R. Plymate, Takuma Uo
Summary: This article discusses the urgent need to explore new actionable targets other than the androgen receptor to improve treatment outcomes for castration-resistant prostate cancer. Tumor metabolism is considered a hallmark of cancer and understanding its relationship with androgen receptor signaling, genetic drivers, and the tumor microenvironment is important for identifying metabolic vulnerabilities. The article also provides an overview of current metabolism-based pharmacological strategies for treating castration-resistant prostate cancer.
Article
Oncology
Kumar Nikhil, Hanan S. Haymour, Mohini Kamra, Kavita Shah
Summary: This study identified that LIMK2 degrades SPOP by direct phosphorylation and creates a feedback loop to promote oncogenicity in prostate cancer. Understanding the relationship between LIMK2 and SPOP provides a powerful opportunity to inhibit LIMK2 and retain WT-SPOP, effectively halting disease progression.
BRITISH JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Ramesh Singh, Huan Meng, Tao Shen, Lance Edward V. Lumahan, Steven Nguyen, Hong Shen, Subhamoy Dasgupta, Li Qin, Dileep Karri, Bokai Zhu, Feng Yang, Cristian Coarfa, Bert W. O'Malley, Ping Yi
Summary: Castration-resistant prostate cancer (CRPC) is a major clinical challenge, and the androgen receptor (AR) is a critical oncogenic player. This study identifies TRAF4 as a key mediator of AR-regulated transcriptional reprogramming in CRPC, promoting its development.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Article
Cell Biology
Mayao Luo, Yifan Zhang, Zhuofan Xu, Chenwei Wu, Yuedian Ye, Rui Liu, Shidong Lv, Qiang Wei
Summary: The combination therapy of tautomycin and enzalutamide could achieve a more comprehensive inhibition of androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC). Enzalutamide enhanced tautomycin-induced AR degradation by competing with residual androgens, while tautomycin decreased ARv7 levels through AR degradation. This combination therapy may represent a new therapeutic strategy for CRPC.
CELL DEATH DISCOVERY
(2022)
Article
Engineering, Biomedical
Nicole L. Habbit, Benjamin Anbiah, Joshita Suresh, Luke Anderson, Megan L. Davies, Iman Hassani, Taraswi M. Ghosh, Michael W. Greene, Balabhaskar Prabhakarpandian, Robert D. Arnold, Elizabeth A. Lipke
Summary: Using a 3D-engineered prostate cancer (PCa) tissue model, this study reveals that the incorporation of fibroblasts promotes PCa aggression by increasing proliferation, significant matrix remodeling, and enrichment of tumorigenic hallmark gene sets. Fibroblasts play an elevated role in indolent disease states and may contribute to the switch from androgen-dependent to castration-resistant PCa.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Oncology
Ann-Yae Na, Soyoung Choi, Eunju Yang, Kwang-Hyeon Liu, Sunghwan Kim, Hyun Jin Jung, Youngshik Choe, Yun-Sok Ha, Tae Gyun Kwon, Jun Nyung Lee, Sangkyu Lee
Summary: The study investigated prostate cancer tissues at different stages using quantitative proteomic technology and identified FOXA1 and HMGN1-3 proteins as significant factors in the progression to CRPC. These proteins could potentially be used as therapeutic targets in clinical treatment.
Article
Medicine, Research & Experimental
Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hye-Jeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim
Summary: The study identified BCT as a potent inhibitor targeting both AR-FL and AR-V7 activities in CRPC, effectively suppressing tumor growth and metastasis. Mechanistically, BCT disrupts the interaction of HSP90 with AR-FL/AR-V7, leading to their degradation and showing promising therapeutic potential against CRPC.
Article
Cell & Tissue Engineering
Yalan Xu, Jie Mu, Zhixia Zhou, Yu Leng, Yali Yu, Xiuyue Song, Aihua Liu, Hai Zhu, Jing Li, Dong Wang
Summary: The study isolated and cultured a novel type of castration-resistant intermediate prostate stem cells that can rapidly proliferate in 2D culture dishes and be maintained for over six months. These stem cells express markers of both basal and luminal cells, and can differentiate into prostate organoids and tissues.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Medicine, Research & Experimental
Cagdas Aktan, Cag Cal, Burcin Kaymaz, Nur Selvi Gunel, Sezgi Kipcak, Buket Ozel, Cumhur Gunduz, Ali Sahin Kucukaslan, Duygu Ayguenes Jafari, Buket Kosova
Summary: In this study, differentially expressed miRNAs that target androgen receptors (ARs) were identified and investigated in castration resistant prostate cancer (CRPC) cells. The expression levels of miR-625-5p and miR-874-3p were significantly increased in CRPC cells compared with androgen dependent cells, and transfection of CRPC cells with anti-miRs suppressed their proliferation and AR protein levels.
Article
Biochemistry & Molecular Biology
Xiong Chen, Guo Yang, Miao Liu, Zhen Quan, Leilei Wang, Chunli Luo, Xiaohou Wu, Yongbo Zheng
Summary: This study suggests that lycopene enhances the antitumor effects of enzalutamide in castration-resistant prostate cancer (CRPC) by reducing AR protein levels through the inhibition of the AKT/EZH2 pathway.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Urology & Nephrology
Oscar Rodriguez Faba, Mark D. Tyson, Walter Artibani, Bernard H. Bochner, Fiona Burkhard, Scott M. Gilbert, Tilman Kaelble, Stephan Madersbacher, Roland Seiler, Ella C. Skinner, George Thalmann, Joachim Thueroff, Peter Wiklund, Richard Hautmann, Joan Palou
WORLD JOURNAL OF UROLOGY
(2019)
Article
Urology & Nephrology
Sebastian Nestler, C. Thomas, A. Neisius, P. Rubenwolf, F. Roos, C. Hampel, J. W. Thueroff
WORLD JOURNAL OF UROLOGY
(2019)
Article
Urology & Nephrology
Sebastian K. Frees, Mohammed M. Kamal, Sebastian Nestler, Patrick M. F. Levien, Samir Bidnur, Walburgis Brenner, Christian Thomas, Wolfgang Jaeger, Joachim W. Thueroff, Frederik C. Roos
INTERNATIONAL JOURNAL OF UROLOGY
(2019)
Article
Urology & Nephrology
Sebastian Nestler, T. Bach, T. Herrmann, S. Jutzi, F. C. Roos, C. Hampel, J. W. Thueroff, C. Thomas, A. Neisius
WORLD JOURNAL OF UROLOGY
(2019)
Review
Genetics & Heredity
Camille Jacques, Melanie Lavaud, Steven Georges, Robel Tesfaye, Marc Baud'huin, Francois Lamoureux, Benjamin Ory
Article
Medicine, General & Internal
Brice Moukengue, Hannah K. Brown, Celine Charrier, Severine Battaglia, Marc Baud'huin, Thibaut Quillard, Therese M. Pham, Ioannis S. Pateras, Vassilis G. Gorgoulis, Thomas Helleday, Dominique Heymann, Ulrika Warpman Berglund, Benjamin Ory, Francois Lamoureux
Review
Cell Biology
Camille Jacques, Robel Tesfaye, Melanie Lavaud, Steven Georges, Marc Baud'huin, Francois Lamoureux, Benjamin Ory
Article
Chemistry, Medicinal
Redouane Tabti, Francois Lamoureux, Celine Charrier, Benjamin Ory, Dominique Heymann, Embarek Bentouhami, Laurent Desaubry
Summary: Current therapeutic approaches for osteoporosis have limitations and potential adverse effects, but some sulfonylamidines have been shown to inhibit the formation of osteoclasts, suggesting potential for the development of new drugs. Compound IN45 demonstrated significant inhibition at a low concentration, indicating promise for anti-osteoporotic drug development.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Cell Biology
Emilien Orgebin, Francois Lamoureux, Bertrand Isidor, Celine Charrier, Benjamin Ory, Frederic Lezot, Marc Baud'huin
Article
Oncology
Mathilde Mullard, Marie Cade, Sarah Morice, Maryne Dupuy, Geoffroy Danieau, Jerome Amiaud, Sarah Renault, Frederic Lezot, Regis Brion, Rose Anne Thepault, Benjamin Ory, Francois Lamoureux, Isabelle Corre, Benedicte Brounais-LeRoyer, Francoise Redini, Franck Verrecchia
Review
Oncology
Louise Marchandet, Morgane Lallier, Celine Charrier, Marc Baud'huin, Benjamin Ory, Francois Lamoureux
Summary: Osteosarcoma is the most common primary bone tumor affecting children and adolescents, with resistance being one of the reasons for treatment failure. Understanding the molecular mechanisms of resistance is key to developing new strategies to improve patient outcomes.
Review
Cell Biology
Morgane Lallier, Louise Marchandet, Brice Moukengue, Celine Charrier, Marc Baud'huin, Franck Verrecchia, Benjamin Ory, Francois Lamoureux
Summary: Osteosarcoma is the most common form of primary bone tumor affecting children and young adults, with a 5-year survival rate of 70%. Heat Shock Proteins play a significant role in cell proliferation, apoptosis inhibition, migration, and drug resistance in osteosarcoma. By studying HSP27, HSP60, HSP70, and HSP90, they can serve as potential clinical uses in osteosarcoma.
Meeting Abstract
Oncology
Emilien Orgebin, Benjamin Ory, Francois Lamoureux, Marie-Francoise O'Donohue, Celine Charrier, Pierre-Emmanuel Gleizes, Bertrand Isidor, Marc Baud'huin
Meeting Abstract
Oncology
Melanie Lavaud, Robel Tesfaye, Steven Georges, Marc Baud'huin, Francois Lamoureux, Benjamin Ory
Review
Urology & Nephrology
Karl F. Kowalewski, Christian Tapking, Svetlana Hetjens, Felix Nickel, Philipp Mandel, Philipp Nuhn, Manuel Ritter, Judd W. Moul, Joachim W. Thueroff, Maximilian C. Kriegmair
EUROPEAN UROLOGY FOCUS
(2019)